PBM PSYENCE BIOMEDICAL LTD

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that management will host 1x1 meetings with investors during the A.G.P. Virtual Healthcare Company Showcase, which is being held May 21, 2024.

For more information, or to register: .

About Psyence Biomed

Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada, is the world’s first life science biotechnology company traded on The Nasdaq Stock Market LLC (“Nasdaq”) (Nasdaq:PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence Biomed is initially focused on mental health disorders in the context of Palliative Care.

Learn more at  and on 

Contact Information

Email:

Media Inquiries:

General Information:

Phone: +1 416-477-1708

Investor Contact:

Jeremy Feffer

Managing Director

LifeSci Advisors



EN
17/05/2024

Underlying

PBMPSYENCE BIOMEDICAL LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PSYENCE BIOMEDICAL LTD

 PRESS RELEASE
Free
PBM PSYENCE BIOMEDI...

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharma...

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone “The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody Aufrichtig NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic ph...

2h / 4m 1 EN
 PRESS RELEASE
Free
PBM PSYENCE BIOMEDI...

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin...

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the successful export of fully GMP-compliant manufactured psilocybin product NPX-5 (1mg and 5mg capsules) to Australia. The product was manufactured at the Psyence Labs Ltd. (“PsyLabs”) GMP-controlled production ...

March 3, 2026 1 EN
 PRESS RELEASE
Free
PBM PSYENCE BIOMEDI...

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strateg...

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds ("PsyLabs") has exercised its rights under a previously disclosed put option agreement (the "Put Option Agreement"), pursuant to which Psyence B...

February 20, 2026 1 EN
 PRESS RELEASE
Free
PBM PSYENCE BIOMEDI...

Psyence BioMed Announces Results of Annual and Special Meeting of Shar...

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “Meeting”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the...

February 17, 2026 1 EN
 PRESS RELEASE
Free
PBM PSYENCE BIOMEDI...

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure St...

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby securing predictable and reliable supply of pharmaceutical grade psychedelics, as the pathway to commercialization unfolds NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company a...

February 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch